Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock Has Consensus Price Target of $12.77 According to Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have earned an average recommendation of “Buy” from the fifteen brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, twelve have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $12.77.

Several analysts have recently weighed in on the stock. Pivotal Research set a $14.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, June 23rd. Robert W. Baird increased their target price on Taysha Gene Therapies from $12.00 to $15.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. The Goldman Sachs Group boosted their price objective on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, June 30th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and set a $11.00 target price on shares of Taysha Gene Therapies in a report on Thursday, July 2nd.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Arizona State Retirement System grew its holdings in shares of Taysha Gene Therapies by 5.4% during the second quarter. Arizona State Retirement System now owns 39,633 shares of the company’s stock valued at $270,000 after purchasing an additional 2,014 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Taysha Gene Therapies by 26.2% during the first quarter. Principal Financial Group Inc. now owns 16,185 shares of the company’s stock valued at $72,000 after acquiring an additional 3,362 shares during the period. Sei Investments Co. raised its stake in shares of Taysha Gene Therapies by 7.6% in the 1st quarter. Sei Investments Co. now owns 51,472 shares of the company’s stock worth $230,000 after buying an additional 3,614 shares in the last quarter. Chicago Partners Investment Group LLC boosted its position in shares of Taysha Gene Therapies by 2.5% during the 1st quarter. Chicago Partners Investment Group LLC now owns 170,751 shares of the company’s stock valued at $763,000 after purchasing an additional 4,210 shares in the last quarter. Finally, Cetera Investment Advisers grew its position in Taysha Gene Therapies by 34.5% in the first quarter. Cetera Investment Advisers now owns 28,450 shares of the company’s stock worth $127,000 after buying an additional 7,296 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Trading Down 13.5%

Shares of TSHA stock opened at $3.58 on Wednesday. The company has a market capitalization of $1.17 billion, a PE ratio of -8.52 and a beta of 1.19. Taysha Gene Therapies has a 52-week low of $3.55 and a 52-week high of $7.30. The business’s fifty day moving average is $5.41 and its 200 day moving average is $5.69. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.76 and a current ratio of 17.76.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, equities research analysts anticipate that Taysha Gene Therapies will post -0.52 EPS for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. The company uses adeno-associated virus-based delivery technologies and other genetic medicine approaches to target conditions with limited or no approved treatment options.

Taysha’s research and development programs have included TSHA-102, an investigational gene therapy being developed for Rett syndrome, as well as programs for other rare neurological disorders.